A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
This study has been terminated.
Sponsor:
Emergent Product Development Seattle LLC
Information provided by (Responsible Party):
Emergent Product Development Seattle LLC
ClinicalTrials.gov Identifier:
NCT01317901
First received: March 15, 2011
Last updated: November 9, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Estimated Study Completion Date: | April 2016 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |